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Background. Enterovirus 71 (EV-71) is a nonenveloped, single-stranded positive-sense RNA virus belonging to genus Enterovius, family Picornaviridae. EV-71 has caused recurrent outbreaks of hand, foot, and mouth disease especially among children in Asia. Some patients develop severe complications, such as meningitis, encephalitis, poliomyelitis-like paralysis, myocarditis, and pulmonary edema. There are currently limited treatment options for EV-71 infection. OSU-03012 is a celecoxib derivative cellular kinase inhibitor with no inhibiting activity on cyclooxygenase that has antiviral activities against a broad-spectrum of viruses, including flaviviruses, filoviruses, and arenaviruses.
Methods. Two clinical isolates of EV-71 obtained from patients with laboratory-confirmed EV-71 infections were included in the study. We evaluated the in vitro anti-EV-71 activity of OSU-03012, using virus yield reduction assays (by quantitative reverse transcription-polymerase chain reaction), cell protection assay, and plaque reduction assay in multiple cell lines.
Results. OSU-03012 inhibited both EV-71 strains in U251 (neuronal) and RD (rhabdomyosarcoma) cells. The half maximal inhibitory concentration (IC 50 ) of OSU-03012 against EV-71 was consistently <2 µM in these cell lines in the virus yield reduction assay. At 2µM of OSU-03012, there was a nearly 2-log reduction in viral RNA load in both U251 and RD cells. There was a dose-dependent increase in the percentage of viable cells after the addition of 0 to 2 µM of OSU-03012 in EV-71-infected U251 and RD cells in the cell protection assay. In the plaque reduction assay, there was >70% reduction in plaque numbers with the addition of 2 µM of OSU-03012.
Conclusion. OSU-03012 exhibits anti-EV-71 activity in vitro. The treatment effects of OSU-03012 should be further evaluated in representative animal models of severe EV-71 infection to provide further data for potential clinical evaluation in the future. Background. In the last years, there has been an increase in incidence of cases of measles in high and middle-income countries. In Argentina, measles elimination was achieved in 2000, with no circulation of measles virus since then; vaccination iscompulsory (two doses MMR vaccine) and coverage is reported to be roughly 85%. The aim of this study was to determine seroprevalence of antibodies to measles in adults, analyzed according to HIV status.
Low Prevalence of Protective Antibodies to Measles Among Young Adults in Argentina
Methods. Cross-sectional study. All serologic tests requested for measles antibodies in patients aged >18 years between January 2015 and December 2017 in an Infectious Diseases Reference Center in Buenos Aires were retrieved and analyzed according to HIV status and age group. All determinations were done with VIDAS¨ Measles IgG, Biomeriex. Chi-squared and Fisher's exact tests were used for comparisons.
Results. We included 2,663 patients with determinations for measles performed in the mentioned period. Of those, 348 were HIV(+), with mean (±SD) age: 34.7(±6.2) years, 85% male (86% MSM), mean (±SD) nadir CD4 (cells/mm 3 ): 369.6(±219.5); 89% VL< 50 copies/mL; and 2,315 were HIV(-), with mean age(±SD): 31(±5.9) years, 67% female. There was a high proportion of seronegative subjects to measles in both groups, but significantly higher in HIV+ patients (40.8% vs. 33.2%; P = 0.005). However, when analyzed by age group, in those <40 years the proportion of seronegativity to measles was higher (HIV+: 45.3% vs. 31.3%, P = 0.02; HIV-: 38.3% vs. 20.2%, P < 0.001; Figure 1 ). Patients older than 50 years (the most prone to having beenexposed to measles virus) had the highest prevalence of measles antibodies (>92% in both groups; Figure 2 ); and those younger than 40, the lowest (55% in HIV+ and 62% in HIV−). Stratification by gender did not change any of these findings. In HIV+ persons, seronegativity to measles was not associated with nadir of CD4 < 200 (P = NS).
Conclusion. We found a very high proportion of subjects without protective antibodies to measles among those <40 years (higher in HIV+ patients). This is interesting since in Argentina the vast majority of people <40 should have been vaccinated atleast once. Lack of circulation of measles might accelerate waning of antibodies. There might be an increased risk of measles in young people, especially in HIV+ persons; measures to evaluate this situation and eventually (re)vaccinate susceptiblepersons is warranted.
